{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:09:31Z","timestamp":1791461371626,"version":"4.3.4"},"reference-count":482,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1124\/pr.112.007278","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T18:39:10Z","timestamp":1375987150000},"page":"809-848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":262,"title":["A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists"],"prefix":"10.1016","volume":"65","author":[{"given":"Martin C.","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans R.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pr.112.007278_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1139\/y92-093","article-title":"Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan","volume":"70","author":"Abdelrahman","year":"1992","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/jpet.108.138073","article-title":"In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance","volume":"326","author":"Abe","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0303-7207(92)90101-B","article-title":"Role of angiotensin II receptor subtypes on the regulation of aldosterone secretion in the adrenal glomerulosa zone in the rat","volume":"90","author":"Aguilera","year":"1992","journal-title":"Mol Cell Endocrinol"},{"key":"10.1124\/pr.112.007278_bib4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/10799899309073697","article-title":"Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor","volume":"13","author":"Aiyar","year":"1993","journal-title":"J Recept Res"},{"key":"10.1124\/pr.112.007278_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.clpt.2004.04.001","article-title":"Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans","volume":"76","author":"Allabi","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/jm9604383","article-title":"Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles","volume":"40","author":"Almansa","year":"1997","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.bcp.2008.07.006","article-title":"The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan","volume":"76","author":"Alonen","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.112.007278_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/hr.2012.17","article-title":"Structural basis for telmisartan-mediated partial activation of PPAR gamma","volume":"35","author":"Amano","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib10","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.112.007278_bib11","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1053\/j.ajkd.2005.08.034","article-title":"Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies","volume":"46","author":"Aranda","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1124\/pr.112.007278_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/FPC.0b013e32833a6d4a","article-title":"A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity","volume":"20","author":"Arsenault","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.112.007278_bib13","first-page":"48","article-title":"Some quantitative uses of drug antagonists","volume":"14","author":"Arunlakshana","year":"1959","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib14","first-page":"1055","article-title":"Inhibitory action of telmisartan on constriction of rat mesenteric artery in vitro","volume":"34","author":"Asano","year":"2006","journal-title":"Jpn Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/aps.2011.100","article-title":"Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics","volume":"32","author":"Bae","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/pr.112.007278_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5414\/CP201467","article-title":"Effects of CYP2C9*1\/*3 and *1\/*13 on the pharmacokinetics of losartan and its active metabolite E-3174","volume":"50","author":"Bae","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib17","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/HYPERTENSIONAHA.111.173542","article-title":"High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-\u03b3 target genes in patients with the metabolic syndrome","volume":"58","author":"B\u00e4hr","year":"2011","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/0091270006297225","article-title":"Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension","volume":"47","author":"Bajcetic","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00005344-200107000-00015","article-title":"Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery","volume":"38","author":"Balt","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00005344-200207000-00007","article-title":"Prejunctional and postjunctional inhibitory actions of eprosartan and candesartan in the isolated rabbit mesenteric artery","volume":"40","author":"Balt","year":"2002","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00004872-200103000-00015","article-title":"Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan, and captopril","volume":"19","author":"Balt","year":"2001","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib22","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/00004872-200112000-00018","article-title":"Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan","volume":"19","author":"Balt","year":"2001","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3317\/jraas.2000.063","article-title":"The pharmacological potency of various AT(1) antagonists assessed by Schild regression technique in man","volume":"1","author":"Belz","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1124\/pr.112.007278_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/cp.1999.v66.a101162","article-title":"Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay","volume":"66","author":"Belz","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib25","first-page":"S45","article-title":"Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers","volume":"11","author":"Belz","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib26","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/HJH.0b013e3282f56ba5","article-title":"Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?","volume":"26","author":"Benson","year":"2008","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib27","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib28","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1021\/jm049024x","article-title":"Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1\/AT2 angiotensin II receptor antagonists","volume":"48","author":"Berellini","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib29","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1021\/jm00074a018","article-title":"A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists","volume":"36","author":"Bernhart","year":"1993","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1254\/jphs.09361FP","article-title":"Engineered mutation of some important amino acids in angiotensin II type 1 (AT1) receptor increases the binding affinity of AT1-receptor antagonists","volume":"113","author":"Bhuiyan","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pr.112.007278_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1254\/jphs.09202FP","article-title":"Constitutively active mutant N111G of angiotensin II type 1 (AT(1)) receptor induces homologous internalization through mediation of AT(1)-receptor antagonist","volume":"111","author":"Bhuiyan","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pr.112.007278_bib32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1254\/jphs.09343SC","article-title":"Internalization of constitutively active N111G MUTANT of AT1 receptor induced by angiotensin II-receptor antagonists candesartan, losartan, and telmisartan: comparison with valsartan","volume":"112","author":"Bhuiyan","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pr.112.007278_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lfs.2009.05.001","article-title":"Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling","volume":"85","author":"Bhuiyan","year":"2009","journal-title":"Life Sci"},{"key":"10.1124\/pr.112.007278_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1248\/bpb.32.416","article-title":"Telmisartan increases the permeability of endothelial cells through zonula occludens-1","volume":"32","author":"Bian","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1124\/pr.112.007278_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s002280050303","article-title":"Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide","volume":"52","author":"Bindschedler","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.atherosclerosis.2007.10.037","article-title":"Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice","volume":"199","author":"Blessing","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.112.007278_bib37","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270008329547","article-title":"Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension","volume":"49","author":"Blumer","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib38","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1210\/endo.130.6.1597161","article-title":"Angiotensin-II-binding sites on hepatocyte nuclei","volume":"130","author":"Booz","year":"1992","journal-title":"Endocrinology"},{"key":"10.1124\/pr.112.007278_bib39","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0026-895X(25)09072-8","article-title":"Modulation of angiotensin II binding affinity by allosteric interaction of polyvinyl sulfate with an intracellular domain of the DuP-753-sensitive angiotensin II receptor of bovine adrenal glomerulosa","volume":"41","author":"Boulay","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0090-9556(24)15292-0","article-title":"Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes","volume":"27","author":"Bourri\u00e9","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0009-9236(97)90029-1","article-title":"Pharmacokinetics of valsartan in patients with liver disease","volume":"62","author":"Brookman","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF00164582","article-title":"Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs","volume":"345","author":"Brooks","year":"1992","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"12 Pt 2, Suppl","key":"10.1124\/pr.112.007278_bib43","doi-asserted-by":"crossref","first-page":"311S","DOI":"10.1016\/S0895-7061(97)00391-9","article-title":"The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations","volume":"10","author":"Brunner","year":"1997","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib44","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1021\/jm00114a021","article-title":"Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives","volume":"34","author":"B\u00fchlmayer","year":"1991","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib45","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(92)90593-S","article-title":"Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier","volume":"219","author":"Bui","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib46","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.103.6.904","article-title":"Angiotensin II type 1 receptor blockers","volume":"103","author":"Burnier","year":"2001","journal-title":"Circulation"},{"key":"10.1124\/pr.112.007278_bib47","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0026-895X(24)09251-4","article-title":"Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization","volume":"59","author":"Caballero","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib48","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/01.CIR.101.10.1199","article-title":"Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents","volume":"101","author":"Caballero","year":"2000","journal-title":"Circulation"},{"key":"10.1124\/pr.112.007278_bib490","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1021\/jm7011563","article-title":"Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems","volume":"51","author":"Cappelli","year":"2008","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib49","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1021\/jm031100t","article-title":"Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT1 angiotensin II receptor antagonists based on the 4-phenylquinoline structure","volume":"47","author":"Cappelli","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib50","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1021\/jm200409s","article-title":"Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-\u03b3","volume":"54","author":"Casimiro-Garcia","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11906-008-0019-9","article-title":"Local adipose tissue renin-angiotensin system","volume":"10","author":"Cassis","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"10.1124\/pr.112.007278_bib52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-3565(25)38210-8","article-title":"Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist","volume":"265","author":"Cazaubon","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib53","doi-asserted-by":"crossref","unstructured":"Challa VR, Ravindra Babu P, Challa SR, Johnson B, and Maheswari C (2013) Pharmacokinetic interaction study between quercetin and valsartan in rats and in vitro models. Drug Dev Ind Pharm DOI 10.3109\/03639045.2012.693502.","DOI":"10.3109\/03639045.2012.693502"},{"issue":"Suppl 11","key":"10.1124\/pr.112.007278_bib54","first-page":"S101","article-title":"Analysis of the effects of candesartan on responses to angiotensin II in the hindquarters vascular bed of the cat","volume":"10","author":"Champion","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/pr.112.007278_bib55","first-page":"E115","article-title":"Responses to angiotensin peptides are mediated by AT1 receptors in the rat","volume":"274","author":"Champion","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.112.007278_bib56","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/01.HYP.30.5.1260","article-title":"Analysis of the effects of candesartan in the mesenteric vascular bed of the cat","volume":"30","author":"Champion","year":"1997","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib57","first-page":"408","article-title":"Biotransformation of irbesartan in man","volume":"26","author":"Chando","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib58","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1124\/dmd.106.012351","article-title":"Rapid identification of P-glycoprotein substrates and inhibitors","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib59","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0922-4106(93)90077-M","article-title":"Characterization of [3H]losartan receptors in isolated rat glomeruli","volume":"247","author":"Chansel","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib60","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/0006-291X(90)91575-D","article-title":"[3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype","volume":"172","author":"Chiu","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib61","first-page":"33","article-title":"Angiotensin II receptor subtypes and their selective nonpeptide ligands","volume":"1","author":"Chiu","year":"1990","journal-title":"Receptor"},{"key":"10.1124\/pr.112.007278_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0022-3565(25)19981-3","article-title":"Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent","volume":"252","author":"Chiu","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib63","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/0006-291X(92)91335-N","article-title":"[125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor","volume":"188","author":"Chiu","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib64","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00228-011-1098-0","article-title":"CYP2C9 3 and 13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects","volume":"68","author":"Choi","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/j.1552-4604.1995.tb04097.x","article-title":"Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753\/MK 954) and its pharmacologically active metabolite EXP3174","volume":"35","author":"Christ","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib66","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-3565(25)38613-1","article-title":"The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753\/MK 954) in the dog","volume":"268","author":"Christ","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib67","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1161\/01.CIR.83.4.1333","article-title":"Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II","volume":"83","author":"Christen","year":"1991","journal-title":"Circulation"},{"key":"10.1124\/pr.112.007278_bib68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0014-2999(95)00237-F","article-title":"Effects of irbesartan (SR47436\/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action","volume":"281","author":"Christophe","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2007.09.013","article-title":"Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells","volume":"198","author":"Cianchetti","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.112.007278_bib70","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/01.HYP.0000168046.19884.6a","article-title":"PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin","volume":"46","author":"Clasen","year":"2005","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib71","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2337\/db07-0839","article-title":"Liver-specific peroxisome proliferator-activated receptor \u03b1 target gene regulation by the angiotensin type 1 receptor blocker telmisartan","volume":"57","author":"Clemenz","year":"2008","journal-title":"Diabetes"},{"key":"10.1124\/pr.112.007278_bib72","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/j.1552-4604.1997.tb04783.x","article-title":"Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist","volume":"37","author":"Colussi","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00210-011-0706-y","article-title":"Local renin-angiotensin systems in the genitourinary tract","volume":"385","author":"Comiter","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib74","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0026-895X(25)08819-4","article-title":"Angiotensin II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways","volume":"41","author":"Crawford","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib75","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1476-5381.1993.tb13877.x","article-title":"Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype","volume":"110","author":"Criscione","year":"1993","journal-title":"Br J Pharmacol"},{"issue":"Suppl 3","key":"10.1124\/pr.112.007278_bib76","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1038\/sj.jhh.1001442","article-title":"The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers","volume":"16","author":"Culman","year":"2002","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib77","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-2999(98)00983-2","article-title":"Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats","volume":"367","author":"Culman","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib78","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s002280050318","article-title":"Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol","volume":"52","author":"Czendlik","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","article-title":"Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population","volume":"20","author":"Dang","year":"2006","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib80","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0090-9556(24)15006-4","article-title":"Disposition of irbesartan, an angiotensin II AT1-receptor antagonist, in mice, rats, rabbits, and macaques","volume":"28","author":"Davi","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0031-6997(24)01458-3","article-title":"International union of pharmacology. XXIII. The angiotensin II receptors","volume":"52","author":"de Gasparo","year":"2000","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.112.007278_bib82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0167-0115(95)00085-P","article-title":"Binding of valsartan to mammalian angiotensin AT1 receptors","volume":"59","author":"de Gasparo","year":"1995","journal-title":"Regul Pept"},{"key":"10.1124\/pr.112.007278_bib83","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00316470","article-title":"Effect of pretreatment with the selective beta 1-adrenoceptor antagonist bisoprolol on the subsequent cardiovascular actions and beta-adrenoceptor subtype specific occupancy of celiprolol in healthy man","volume":"44","author":"de Mey","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib84","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2125.1995.tb05802.x","article-title":"Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers","volume":"40","author":"De Smet","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib85","first-page":"S37","article-title":"Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment","volume":"11","author":"de Zeeuw","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib86","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1124\/dmd.110.037457","article-title":"Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach","volume":"39","author":"Deguchi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/01.HYP.25.1.14","article-title":"Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers","volume":"25","author":"Delacr\u00e9taz","year":"1995","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib88","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0922-4106(93)90071-G","article-title":"Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436","volume":"247","author":"Delis\u00e9e","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib89","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/00004872-200206000-00027","article-title":"Comparison of the vascular and antiadrenergic activities of four angiotensin II type 1 antagonists in the pithed rat","volume":"20","author":"Dendorfer","year":"2002","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib90","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1517\/17425255.2010.494597","article-title":"Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties","volume":"6","author":"Deppe","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/pr.112.007278_bib91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1476-5381.1994.tb16191.x","article-title":"BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174","volume":"113","author":"Dickinson","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib92","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3233\/JAD-2010-091552","article-title":"Antihypertensive treatments, cognitive decline, and dementia","volume":"20","author":"Duron","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.1124\/pr.112.007278_bib93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0022-3565(25)11212-3","article-title":"Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566","volume":"260","author":"Edwards","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib94","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0022-3565(25)11466-3","article-title":"Characterization of renal angiotensin II receptors using subtype selective antagonists","volume":"260","author":"Edwards","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib95","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0022-3565(25)12239-8","article-title":"Interaction of nonpeptide angiotensin II receptor antagonists with the urate transporter in rat renal brush-border membranes","volume":"276","author":"Edwards","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib96","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/jhg.2012.63","article-title":"Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure","volume":"57","author":"Endo","year":"2012","journal-title":"J Hum Genet"},{"key":"10.1124\/pr.112.007278_bib97","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.vph.2006.05.002","article-title":"Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists","volume":"45","author":"Erbe","year":"2006","journal-title":"Vascul Pharmacol"},{"key":"10.1124\/pr.112.007278_bib98","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.coph.2006.11.008","article-title":"Metabolic actions of angiotensin receptor antagonists: PPAR-\u03b3 agonist actions or a class effect?","volume":"7","author":"Ernsberger","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib99","first-page":"F411","article-title":"Angiotensin II receptor subtypes in cultured rat renal mesangial cells","volume":"263","author":"Ernsberger","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.112.007278_bib100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1042\/cs0990331","article-title":"Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration","volume":"99","author":"Fabiani","year":"2000","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/pr.112.007278_bib101","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1097\/01.hjh.0000249704.34607.4c","article-title":"Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil","volume":"24","author":"Faure","year":"2006","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib102","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/pr.112.007278_bib103","doi-asserted-by":"crossref","first-page":"12846","DOI":"10.1074\/jbc.270.21.12846","article-title":"The docking of Arg2 of angiotensin II with Asp281 of AT1 receptor is essential for full agonism","volume":"270","author":"Feng","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.112.007278_bib104","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/mol.105.011601","article-title":"Single mutations at Asn295 and Leu305 in the cytoplasmic half of transmembrane \u03b1-helix domain 7 of the AT1 receptor induce promiscuous agonist specificity for angiotensin II fragments: a pseudo-constitutive activity","volume":"68","author":"Feng","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0922-4106(93)90170-E","article-title":"Angiotensin AT1 receptors mediate a positive inotropic effect of angiotensin II in guinea pig atria","volume":"245","author":"Feolde","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib106","first-page":"197","article-title":"Angiotensin II-inhibiting drugs have no effect on intraneuronal A\u03b2 or oligomeric A\u03b2 levels in a triple transgenic mouse model of Alzheimer\u2019s disease","volume":"3","author":"Ferrington","year":"2011","journal-title":"Am J Transl Res"},{"key":"10.1124\/pr.112.007278_bib107","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0014-2999(98)00965-0","article-title":"Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells","volume":"367","author":"Fierens","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1067\/mcp.2002.127945","article-title":"Evaluation of potential losartan-phenytoin drug interactions in healthy volunteers","volume":"72","author":"Fischer","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib109","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/jcbfm.2008.158","article-title":"Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells","volume":"29","author":"Fleegal-DeMotta","year":"2009","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1124\/pr.112.007278_bib110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s002280050259","article-title":"Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man","volume":"52","author":"Flesch","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib111","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0922-4106(95)90121-3","article-title":"Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells","volume":"289","author":"Flesch","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib112","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1055\/s-0029-1237359","article-title":"Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients","volume":"41","author":"Fogari","year":"2009","journal-title":"Horm Metab Res"},{"key":"10.1124\/pr.112.007278_bib113","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/01.HYP.34.1.138","article-title":"Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats","volume":"34","author":"Fortu\u00f1o","year":"1999","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib114","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","article-title":"The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans","volume":"54","author":"Fromm","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/pr.112.007278_bib115","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1211\/0022357001774994","article-title":"Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man","volume":"52","author":"Fuchs","year":"2000","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/pr.112.007278_bib116","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.febslet.2004.09.027","article-title":"An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes","volume":"576","author":"Fujimoto","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1124\/pr.112.007278_bib117","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/hr.2010.135","article-title":"A small difference in the molecular structure of angiotensin II receptor blockers induces AT\u2081 receptor-dependent and -independent beneficial effects","volume":"33","author":"Fujino","year":"2010","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib118","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1007\/s10620-007-9741-4","article-title":"Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats","volume":"52","author":"Fujita","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1124\/pr.112.007278_bib119","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.biopha.2010.09.014","article-title":"The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice","volume":"64","author":"Fukuda","year":"2010","journal-title":"Biomed Pharmacother"},{"key":"10.1124\/pr.112.007278_bib120","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1124\/dmd.107.019026","article-title":"Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes","volume":"36","author":"Fukuda","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib121","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004872-200103001-00007","article-title":"The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo","volume":"19","author":"Fukuhara","year":"2001","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib122","first-page":"193","article-title":"Telmisartan as a peroxisome proliferator-activated receptor-\u03b3 ligand is a new target in the treatment of human renal cell carcinoma","volume":"2","author":"Funao","year":"2009","journal-title":"Mol Med Report"},{"key":"10.1124\/pr.112.007278_bib123","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000028308","article-title":"Effects of eprosartan on glomerular injury in rats with reduced renal mass","volume":"59","author":"Gandhi","year":"1999","journal-title":"Pharmacology"},{"key":"10.1124\/pr.112.007278_bib124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1677\/joe.0.1540133","article-title":"Characterization of the AT1 angiotensin II receptor expressed in guinea pig liver","volume":"154","author":"Garc\u00eda-S\u00e1inz","year":"1997","journal-title":"J Endocrinol"},{"key":"10.1124\/pr.112.007278_bib125","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1124\/dmd.111.039842","article-title":"The impact of hepatic uptake on the pharmacokinetics of organic anions","volume":"39","author":"Gardiner","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib126","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00210-003-0813-5","article-title":"Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution","volume":"369","author":"Gerloff","year":"2004","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1527-3466.2004.tb00146.x","article-title":"Candesartan","volume":"22","author":"Gleiter","year":"2004","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/pr.112.007278_bib128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00210-002-0545-y","article-title":"Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats","volume":"365","author":"Gohlke","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0022-3565(24)29352-6","article-title":"AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats","volume":"298","author":"Gohlke","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BF00192369","article-title":"Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist","volume":"49","author":"Goldberg","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib131","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0009-9236(96)80004-X","article-title":"Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174","volume":"59","author":"Goldberg","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib132","first-page":"126","article-title":"Effect of valsartan on renal handling of uric acid in healthy subjects","volume":"13","author":"Gonz\u00e1lez-Ortiz","year":"2000","journal-title":"J Nephrol"},{"key":"10.1124\/pr.112.007278_bib133","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0022-3565(25)23835-6","article-title":"Time course of losartan blockade of angiotensin II hypertension versus blockade of angiotensin II fast pressor effects","volume":"271","author":"Gorbea-Oppliger","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib134","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1067\/mcp.2000.111182","article-title":"Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers","volume":"68","author":"Gossmann","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cbi.2010.03.030","article-title":"Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes","volume":"185","author":"Goyal","year":"2010","journal-title":"Chem Biol Interact"},{"key":"10.1124\/pr.112.007278_bib136","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/sj.bjp.0702722","article-title":"Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries","volume":"127","author":"Garcha","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib137","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1097\/00004872-200311000-00028","article-title":"Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats","volume":"21","author":"Groth","year":"2003","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib138","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s002100100396","article-title":"Differential effects of eprosartan and losartan at prejunctional angiotensin II receptors","volume":"363","author":"Guimar\u00e3es","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib139","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2005.10.009","article-title":"Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance","volume":"111","author":"Guo","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1515\/CCLM.2009.019","article-title":"No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects","volume":"47","author":"Guo","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1124\/pr.112.007278_bib141","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00228-009-0624-9","article-title":"Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers","volume":"65","author":"Han","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib142","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.tpj.6500063","article-title":"CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro","volume":"1","author":"Hanatani","year":"2001","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/pr.112.007278_bib143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0922-4106(95)90103-5","article-title":"Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor","volume":"289","author":"Hara","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib144","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neulet.2009.08.043","article-title":"Cerebroprotective action of telmisartan by inhibition of macrophages\/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism","volume":"464","author":"Haraguchi","year":"2009","journal-title":"Neurosci Lett"},{"key":"10.1124\/pr.112.007278_bib145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00005344-199702000-00019","article-title":"The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist","volume":"29","author":"Hashimoto","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib146","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-2999(98)00134-4","article-title":"Characterization and distribution of angiotensin II receptor subtypes in the mouse brain","volume":"348","author":"H\u00e4user","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib147","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1476-5381.1992.tb09039.x","article-title":"Pharmacological characterization of angiotensin-induced depolarizations of rat superior cervical ganglion in vitro","volume":"105","author":"Hawcock","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib148","first-page":"620","article-title":"Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd Communication: hemodynamic effects of valsartan in rats and dogs","volume":"47","author":"Hayashi","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pr.112.007278_bib149","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1161\/HYPERTENSIONAHA.109.143958","article-title":"Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-\u03b4-dependent pathways","volume":"55","author":"He","year":"2010","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib150","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/0091270007307880","article-title":"Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects","volume":"48","author":"He","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib151","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(94)90394-8","article-title":"Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro","volume":"251","author":"Herbert","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib152","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0014-2999(99)00662-7","article-title":"The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling","volume":"384","author":"Hines","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib153","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.atherosclerosis.2008.12.036","article-title":"Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K\/Akt pathway","volume":"205","author":"Honda","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1124\/pr.112.007278_bib154","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-005-0976-8","article-title":"CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population","volume":"61","author":"Hong","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.HYP.19.3.221","article-title":"Aldosterone regulation of gene transcription leading to control of ion transport","volume":"19","author":"Horisberger","year":"1992","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib156","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.neuroscience.2005.03.054","article-title":"Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia","volume":"134","author":"Hosomi","year":"2005","journal-title":"Neuroscience"},{"key":"10.1124\/pr.112.007278_bib157","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1751-7176.2010.00335.x","article-title":"Telmisartan effects on insulin resistance in obese or overweight adults without diabetes or hypertension","volume":"12","author":"Hsueh","year":"2010","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1124\/pr.112.007278_bib158","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/10641960600946171","article-title":"Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers","volume":"28","author":"Huber","year":"2006","journal-title":"Clin Exp Hypertens"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib159","first-page":"S19","article-title":"Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers","volume":"11","author":"H\u00fcbner","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib160","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0090-9556(25)08163-2","article-title":"N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans","volume":"21","author":"Huskey","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib161","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0014-2999(97)01542-2","article-title":"Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT1 receptor subtype","volume":"343","author":"Huwiler","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib162","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/HJH.0b013e3282f52c36","article-title":"Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-\u03b3-modulating activity, on nitric oxide bioavailability and atherosclerotic change","volume":"26","author":"Ikejima","year":"2008","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib163","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cardiores.2006.07.014","article-title":"Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor \u03b3","volume":"72","author":"Imayama","year":"2006","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"10.1124\/pr.112.007278_bib164","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1038\/sj.jhh.1000749","article-title":"Pharmacologic properties of candesartan cilexetil\u2014possible mechanisms of long-acting antihypertensive action","volume":"13","author":"Inada","year":"1999","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib165","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0022-3565(25)38647-7","volume":"268","author":"Inada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib166","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1124\/dmd.105.009175","article-title":"Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans","volume":"34","author":"Ishiguro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib167","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1124\/dmd.107.018903","article-title":"Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide","volume":"36","author":"Ishiguro","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib168","doi-asserted-by":"crossref","first-page":"11892","DOI":"10.1074\/jbc.M109.072629","article-title":"Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine","volume":"285","author":"Ishizuka","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.112.007278_bib169","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1124\/dmd.111.041475","article-title":"Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism","volume":"40","author":"Ishizuka","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0922-4106(95)90084-5","article-title":"A long-term receptor stimulation is requisite for angiotensin II-dependent DNA synthesis in vascular smooth muscle cells from spontaneously hypertensive rats","volume":"291","author":"Itazaki","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib171","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1291\/hypres.18.69","article-title":"Effects of the non-peptide angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension","volume":"18","author":"Ito","year":"1995","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib172","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1097\/01.hjh.0000244952.54738.f6","article-title":"The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage","volume":"24","author":"Iwai","year":"2006","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib173","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.amjhyper.2006.12.010","article-title":"TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation","volume":"20","author":"Iwai","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib174","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.106.112755","article-title":"Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter","volume":"320","author":"Iwanaga","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib175","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1097\/HJH.0b013e32833a551a","article-title":"Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-\u03b3 activation in diabetic mice","volume":"28","author":"Iwanami","year":"2010","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib176","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1097\/01.hjh.0000242405.68461.84","article-title":"Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-\u03b3 activation","volume":"24","author":"Janke","year":"2006","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib177","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0031-6997(25)06844-9","article-title":"International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology","volume":"47","author":"Jenkinson","year":"1995","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.112.007278_bib178","doi-asserted-by":"crossref","first-page":"16533","DOI":"10.1016\/S0021-9258(19)89420-6","article-title":"Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug losartan","volume":"269","author":"Ji","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.112.007278_bib179","first-page":"323","article-title":"Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations","volume":"64","author":"Jiang","year":"2009","journal-title":"Pharmazie"},{"key":"10.1124\/pr.112.007278_bib180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jjp.75.259","article-title":"Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo","volume":"75","author":"Jin","year":"1997","journal-title":"Jpn J Pharmacol"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib181","first-page":"S31","article-title":"Pharmacokinetic drug interaction studies with candesartan cilexetil","volume":"11","author":"Jonkman","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib182","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1097\/HJH.0b013e32834c46fd","article-title":"Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker","volume":"29","author":"Kajiya","year":"2011","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib183","first-page":"41","article-title":"Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers","volume":"25","author":"Kakuta","year":"2005","journal-title":"Int J Clin Pharmacol Res"},{"key":"10.1124\/pr.112.007278_bib184","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lfs.2009.11.006","article-title":"Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes","volume":"86","author":"Kamiyama","year":"2010","journal-title":"Life Sci"},{"key":"10.1124\/pr.112.007278_bib185","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2133\/dmpk.22.267","article-title":"Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes","volume":"22","author":"Kamiyama","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib186","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/HYPERTENSIONAHA.109.132886","article-title":"Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation","volume":"54","author":"Kappert","year":"2009","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib187","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1097\/HJH.0b013e32834cf1c0","article-title":"Morning blood pressure surge, morning platelet aggregation, and silent cerebral infarction in older Japanese hypertensive patients","volume":"29","author":"Kario","year":"2011","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib188","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12325-011-0098-x","article-title":"Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin","volume":"29","author":"Kasichayanula","year":"2012","journal-title":"Adv Ther"},{"key":"10.1124\/pr.112.007278_bib189","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002280050405","article-title":"Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174","volume":"53","author":"Kaukonen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0009-9236(97)90120-X","article-title":"Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers","volume":"62","author":"Kazierad","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib191","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/j.1552-4604.1998.tb04473.x","article-title":"Eprosartan does not affect the pharmacodynamics of warfarin","volume":"38","author":"Kazierad","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib192","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0022-3565(25)24563-3","article-title":"Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist","volume":"272","author":"Keiser","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib193","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/mol.65.1.2","article-title":"Efficacy as a vector: the relative prevalence and paucity of inverse agonism","volume":"65","author":"Kenakin","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib194","series-title":"Pharmacological Analysis of Drug-Receptor Interaction","author":"Kenakin","year":"1987"},{"key":"10.1124\/pr.112.007278_bib195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0b013e3182576098","article-title":"Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan","volume":"60","author":"Kim","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib196","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/hr.2012.63","article-title":"Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT\u2081 receptor in the rostral ventrolateral medulla of hypertensive rats","volume":"35","author":"Kishi","year":"2012","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib197","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10641960903254430","article-title":"Clinical and pharmacotherapeutic relevance of the double-chain domain of the angiotensin II type 1 receptor blocker olmesartan","volume":"32","author":"Kiya","year":"2010","journal-title":"Clin Exp Hypertens"},{"key":"10.1124\/pr.112.007278_bib198","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.109.002014","article-title":"Xenobiotic, bile acid, and cholesterol transporters: function and regulation","volume":"62","author":"Klaassen","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.112.007278_bib199","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.24.4.467","article-title":"Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats","volume":"24","author":"Kline","year":"1994","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0006-2952(96)00691-0","article-title":"Angiotensin type-1 (AT1) receptor gene expression in primarily cultured human arterial umbilical endothelial cells","volume":"53","author":"Ko","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.112.007278_bib201","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2133\/dmpk.23.115","article-title":"The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan","volume":"23","author":"Kobayashi","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib202","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/ajh.2008.27","article-title":"Cardioprotective mechanism of telmisartan via PPAR-\u03b3-eNOS pathway in dahl salt-sensitive hypertensive rats","volume":"21","author":"Kobayashi","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib203","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm960547h","article-title":"Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres","volume":"39","author":"Kohara","year":"1996","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib204","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/00004872-200106001-00002","article-title":"In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist","volume":"19","author":"Koike","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/pr.112.007278_bib205","first-page":"594","article-title":"Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs","volume":"46","author":"Kondo","year":"1996","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pr.112.007278_bib206","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/j.1552-4604.1995.tb04018.x","article-title":"Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin","volume":"35","author":"Kong","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib207","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1592\/phco.19.8.612.31518","article-title":"Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease","volume":"19","author":"Kovacs","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1124\/pr.112.007278_bib208","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00044011-200626010-00004","article-title":"Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects","volume":"26","author":"Kreutz","year":"2006","journal-title":"Clin Drug Investig"},{"key":"10.1124\/pr.112.007278_bib209","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0022-3565(25)09579-5","article-title":"Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine","volume":"273","author":"Krieter","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib210","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/jm00064a011","article-title":"Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles","volume":"36","author":"Kubo","year":"1993","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib211","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/0886022X.2010.501936","article-title":"Ang II enhances tubular cell Ets-1 expression and associated down stream signaling is mediated through AT1 receptors","volume":"32","author":"Kumar","year":"2010","journal-title":"Ren Fail"},{"key":"10.1124\/pr.112.007278_bib212","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF03190880","article-title":"Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data","volume":"33","author":"Kumar","year":"2008","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib213","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib214","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejphar.2011.07.014","article-title":"Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models","volume":"669","author":"Kusumoto","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib215","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1161\/HYPERTENSIONAHA.111.176263","article-title":"Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-\u03b3\/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade","volume":"59","author":"Kusunoki","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib216","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0014-2999(94)00484-6","article-title":"Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models","volume":"264","author":"Lacour","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib217","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1097\/00004872-200106001-00004","article-title":"The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction","volume":"19","author":"Laeis","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/pr.112.007278_bib218","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1139\/y98-002","article-title":"Inhibitory effects of candesartan on responses to angiotensin peptides in the hindquarters vascular bed of the cat","volume":"76","author":"Lambert","year":"1998","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib219","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005344-199711000-00008","article-title":"Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model","volume":"30","author":"Lankford","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib220","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/sj.bjp.0707323","article-title":"Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor","volume":"151","author":"Le","year":"2007","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib221","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1021\/jm9904147","article-title":"Synthesis and pharmacological evaluation of new pyrazolidine-3, 5-diones as AT(1) angiotensin II receptor antagonists","volume":"43","author":"Le Bourdonnec","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib222","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0091270002239710","article-title":"Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans","volume":"43","author":"Lee","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib223","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1592\/phco.23.6.720.32187","article-title":"Losartan and E3174 pharmacokinetics in cytochrome P450 2C9*1\/*1, *1\/*2, and *1\/*3 individuals","volume":"23","author":"Lee","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1124\/pr.112.007278_bib224","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1161\/01.HYP.37.3.981","article-title":"Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade","volume":"37","author":"Leenen","year":"2001","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib225","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1021\/bi0159581","article-title":"Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662","volume":"41","author":"Leesnitzer","year":"2002","journal-title":"Biochemistry"},{"key":"10.1124\/pr.112.007278_bib226","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S0022-3565(25)39603-5","article-title":"Characterization of angiotensin II receptors in smooth muscle preparations of the guinea pig in vitro","volume":"267","author":"Leung","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib227","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ajh\/5.9.648","article-title":"AT1 receptors mediate the release of prostaglandins in porcine smooth muscle cells and rat astrocytes","volume":"5","author":"Leung","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib228","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00894-009-0612-0","article-title":"Characterization of the binding of angiotensin II receptor blockers to human serum albumin using docking and molecular dynamics simulation","volume":"16","author":"Li","year":"2010","journal-title":"J Mol Model"},{"key":"10.1124\/pr.112.007278_bib229","first-page":"165","article-title":"[Effects of telmisartan on voltage-gated Kv1.3 and Kv1.5 potassium channels expressed in Xenopus oocytes]","volume":"37","author":"Li","year":"2009","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1124\/pr.112.007278_bib230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(24)35282-6","article-title":"Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation","volume":"292","author":"Li","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib231","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1472-8206.2001.00018.x","article-title":"Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries","volume":"15","author":"Li","year":"2001","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib232","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0361-9230(93)90036-B","article-title":"Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat","volume":"30","author":"Li","year":"1993","journal-title":"Brain Res Bull"},{"key":"10.1124\/pr.112.007278_bib233","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/00498250903134435","article-title":"Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects","volume":"39","author":"Li","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.112.007278_bib234","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1021\/jm00092a017","article-title":"Nonpeptide angiotensin II receptor antagonists: synthetic and computational chemistry of N-[[4-[2-(2H-tetrazol-5-yl)-1-cycloalken-1- yl]phenyl]methyl]imidazole derivatives and their in vitro activity","volume":"35","author":"Lin","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib235","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1097\/01.hjh.0000242415.73406.17","article-title":"Telmisartan inhibits beta2-integrin MAC-1 expression in human T-lymphocytes","volume":"24","author":"Link","year":"2006","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib236","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","article-title":"Regulation of uric acid excretion by the kidney","volume":"14","author":"Lipkowitz","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1124\/pr.112.007278_bib237","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0090-6980(92)90070-A","article-title":"DuP 753, the selective angiotensin II receptor blocker, is a competitive antagonist to human platelet thromboxane A2\/prostaglandin H2 (TP) receptors","volume":"44","author":"Liu","year":"1992","journal-title":"Prostaglandins"},{"key":"10.1124\/pr.112.007278_bib238","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1124\/jpet.107.130294","article-title":"Progress in brain penetration evaluation in drug discovery and development","volume":"325","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib239","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90892-L","article-title":"Antagonist effect of losartan on angiotensin II induced contraction in five isolated smooth muscle assays","volume":"240","author":"Liu","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib240","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1476-5381.1992.tb14322.x","article-title":"Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action","volume":"106","author":"Liu","year":"1992","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib241","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib242","first-page":"751","article-title":"[Effects of telmisartan on 4-Aminopyridine-sensitive voltage dependant potassium channel of lymphocyte derived from spontaneously hypertensive rat]","volume":"38","author":"Luo","year":"2010","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1124\/pr.112.007278_bib243","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00004872-199210120-00005","article-title":"Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor","volume":"10","author":"Lyall","year":"1992","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib244","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0008-6363(99)00249-7","article-title":"Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase","volume":"44","author":"MaassenvandenBrink","year":"1999","journal-title":"Cardiovasc Res"},{"key":"10.1124\/pr.112.007278_bib245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00004872-199402000-00008","article-title":"Effects of losartan (DuP753) and enalaprilat on the mean arterial pressure response to phenylephrine","volume":"12","author":"Madwed","year":"1994","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib246","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clpt.2006.01.011","article-title":"Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril","volume":"79","author":"Maeda","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib247","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0895-7061(99)00133-8","article-title":"Assessment of angiotensin II receptor blockade in humans using a standardized angiotensin II receptor-binding assay","volume":"12","author":"Maillard","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib248","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1124\/jpet.102.036772","article-title":"In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist","volume":"302","author":"Maillard","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib249","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1067\/mcp.2002.121425","article-title":"Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing","volume":"71","author":"Maillard","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib250","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2125.1998.00722.x","article-title":"Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man","volume":"45","author":"Malerczyk","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib251","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0149-2918(00)83062-3","article-title":"Effects of losartan and candesartan monotherapy and losartan\/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension","volume":"22","author":"Manolis","year":"2000","journal-title":"Clin Ther"},{"key":"10.1124\/pr.112.007278_bib252","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/j.1552-4604.1998.tb04422.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects","volume":"38","author":"Marino","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib253","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/j.1552-4604.1998.tb04434.x","article-title":"Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis","volume":"38","author":"Marino","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib254","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/00003088-200140080-00004","article-title":"Drug interactions with irbesartan","volume":"40","author":"Marino","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib255","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/j.1552-4604.1998.tb04401.x","article-title":"Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment","volume":"38","author":"Martin","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib256","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2125.1997.00608.x","article-title":"Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers","volume":"43","author":"Martin","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib257","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1139\/y95-058","article-title":"Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo","volume":"73","author":"Martineau","year":"1995","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib258","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/jm00061a014","article-title":"Molecular shape comparison of angiotensin II receptor antagonists","volume":"36","author":"Masek","year":"1993","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib259","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/147323000703500407","volume":"35","author":"Matsui","year":"2007","journal-title":"J Int Med Res"},{"key":"10.1124\/pr.112.007278_bib260","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1161\/ATVBAHA.110.222067","article-title":"Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-\u03b3 in macrophages","volume":"31","author":"Matsumura","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.112.007278_bib261","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/01.HYP.33.3.850","article-title":"Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists","volume":"33","author":"Mazzolai","year":"1999","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib262","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/00912709922007886","article-title":"The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers","volume":"39","author":"Meadowcroft","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib263","first-page":"555","article-title":"Local action of the renin angiotensin system in the porcine ophthalmic circulation: effects of ACE-inhibitors and angiotensin receptor antagonists","volume":"36","author":"Meyer","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1124\/pr.112.007278_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00169183","article-title":"Classification of alpha 1-adrenoceptor subtypes","volume":"352","author":"Michel","year":"1995","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib265","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/HYPERTENSIONAHA.112.192401","article-title":"Peroxisome proliferator-activated receptor-\u03b3 activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice","volume":"59","author":"Min","year":"2012","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib266","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.fjc.0000180902.78230.fd","article-title":"A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker","volume":"46","author":"Mire","year":"2005","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib267","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cca.2008.09.020","article-title":"Telmisartan pharmacokinetics in Japanese renal transplant recipients","volume":"399","author":"Miura","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1124\/pr.112.007278_bib268","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2710.2009.01053.x","article-title":"Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients","volume":"34","author":"Miura","year":"2009","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/pr.112.007278_bib269","doi-asserted-by":"crossref","first-page":"19288","DOI":"10.1074\/jbc.M602144200","article-title":"Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor","volume":"281","author":"Miura","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1124\/pr.112.007278_bib270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1470320310370852","article-title":"Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects","volume":"12","author":"Miura","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1124\/pr.112.007278_bib271","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1210\/me.2007-0312","article-title":"Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state","volume":"22","author":"Miura","year":"2008","journal-title":"Mol Endocrinol"},{"key":"10.1124\/pr.112.007278_bib272","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbrc.2009.11.008","article-title":"Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors","volume":"391","author":"Miura","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib273","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/hr.2012.147","article-title":"Unique Binding Behavior of the Recently Approved Angiotensin II Receptor Blocker Azilsartan Compared With That of Candesartan","volume":"36","author":"Miura","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib274","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1291\/hypres.26.937","article-title":"Molecular analysis of the structure and function of the angiotensin II type 1 receptor","volume":"26","author":"Miura","year":"2003","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib275","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(95)00401-6","article-title":"Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist","volume":"285","author":"Mizuno","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib276","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbrc.2008.08.032","article-title":"Telmisartan prevented cognitive decline partly due to PPAR-\u03b3 activation","volume":"375","author":"Mogi","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib277","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/00005344-200006000-00012","article-title":"Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation","volume":"35","author":"Mont\u00f3n","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib278","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-9236(97)90180-6","article-title":"The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects","volume":"61","author":"Morgan","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib279","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.HYP.33.6.1406","article-title":"Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin","volume":"33","author":"Morsing","year":"1999","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib280","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/phrs.2000.0767","article-title":"Central inhibition of AT1receptors by eprosartan\u2014in vitro autoradiography in the brain","volume":"43","author":"Muders","year":"2001","journal-title":"Pharmacol Res"},{"key":"10.1124\/pr.112.007278_bib281","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02570503","article-title":"Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects","volume":"47","author":"M\u00fcller","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib282","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s002280050317","article-title":"Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects","volume":"52","author":"M\u00fcller","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib283","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1992.56","article-title":"Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist","volume":"51","author":"Munafo","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib284","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/01.ATV.0000240050.15321.fe","article-title":"Angiotensin II type 1 receptor-mediated inflammation is required for choroidal neovascularization","volume":"26","author":"Nagai","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1124\/pr.112.007278_bib285","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/dmd.105.008888","article-title":"OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker","volume":"34","author":"Nakagomi-Hagihara","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib286","first-page":"H2297","article-title":"Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters","volume":"267","author":"Nakamura","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.112.007278_bib287","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1254\/jphs.10064SC","article-title":"Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters","volume":"114","author":"Nakamura","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pr.112.007278_bib288","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/hr.2009.95","article-title":"Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-\u03b3","volume":"32","author":"Nakano","year":"2009","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib289","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00019501-199706000-00003","article-title":"Role of the angiotensin II type 1 receptor in preconditioning against infarction","volume":"8","author":"Nakano","year":"1997","journal-title":"Coron Artery Dis"},{"key":"10.1124\/pr.112.007278_bib290","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00498250500158175","article-title":"Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes","volume":"35","author":"Nakashima","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.112.007278_bib291","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00266358","article-title":"Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects","volume":"42","author":"Nakashima","year":"1992","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib292","first-page":"62","article-title":"The clinical pharmacology of losartan in Japanese subjects and patients","volume":"2","author":"Nakashima","year":"1996","journal-title":"Blood Press Suppl"},{"key":"10.1124\/pr.112.007278_bib293","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5551\/jat.14.133","article-title":"Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma","volume":"14","author":"Nakaya","year":"2007","journal-title":"J Atheroscler Thromb"},{"key":"10.1124\/pr.112.007278_bib294","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1474-8673.2004.00301.x","article-title":"AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease","volume":"23","author":"Nap","year":"2003","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1124\/pr.112.007278_bib295","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1097\/00004872-200209000-00028","article-title":"Sympatholytic properties of several AT1-receptor antagonists in the isolated rabbit thoracic aorta","volume":"20","author":"Nap","year":"2002","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib296","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.112.007278_bib297","first-page":"7","article-title":"Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116","volume":"5","author":"Nishikawa","year":"1994","journal-title":"Blood Press Suppl"},{"key":"10.1124\/pr.112.007278_bib298","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0006-8993(00)02377-5","article-title":"Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors","volume":"871","author":"Nishimura","year":"2000","journal-title":"Brain Res"},{"key":"10.1124\/pr.112.007278_bib299","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0090-9556(24)13658-6","article-title":"Both cMOAT\/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan","volume":"28","author":"Nishino","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib300","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.nucmedbio.2012.06.012","article-title":"Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques","volume":"39","author":"Noda","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1124\/pr.112.007278_bib301","doi-asserted-by":"crossref","first-page":"16435","DOI":"10.1021\/bi961593m","article-title":"The active state of the AT1 angiotensin receptor is generated by angiotensin II induction","volume":"35","author":"Noda","year":"1996","journal-title":"Biochemistry"},{"key":"10.1124\/pr.112.007278_bib302","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-2952(93)90420-2","article-title":"Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist","volume":"46","author":"Noda","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"Suppl A","key":"10.1124\/pr.112.007278_bib303","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/S0149-2918(04)90141-5","article-title":"Antagonizing the angiotensin II subtype I Receptor: a focus on olmesartan medoxomil","volume":"26","author":"Nussberger","year":"2004","journal-title":"Clin Ther"},{"key":"10.1124\/pr.112.007278_bib304","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3940(91)90420-X","article-title":"Distribution of angiotensin II receptor subtypes in rat brain nuclei","volume":"132","author":"Oberm\u00fcller","year":"1991","journal-title":"Neurosci Lett"},{"key":"10.1124\/pr.112.007278_bib305","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/00005344-199509000-00021","article-title":"Persistent inhibition of the pressor and aldosterone responses to angiotensin-II by TCV-116 in normotensive subjects","volume":"26","author":"Ogihara","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib306","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000139534","article-title":"Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade","volume":"55","author":"Ohlstein","year":"1997","journal-title":"Pharmacology"},{"key":"10.1124\/pr.112.007278_bib307","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0022-3565(25)10800-8","article-title":"The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism","volume":"262","author":"Ohlstein","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib308","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.bbrc.2010.11.139","article-title":"Unique \u201cdelta lock\u201d structure of telmisartan is involved in its strongest binding affinity to angiotensin II type 1 receptor","volume":"404","author":"Ohno","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib309","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2125.1993.tb05696.x","article-title":"Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans","volume":"35","author":"Ohtawa","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib310","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.110.176636","article-title":"In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies","volume":"336","author":"Ojima","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib311","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(96)00837-0","article-title":"Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor","volume":"319","author":"Ojima","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib312","first-page":"F515","article-title":"Angiotensin II responses in AT1A receptor-deficient mice: a role for AT1B receptors in blood pressure regulation","volume":"272","author":"Oliverio","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.112.007278_bib313","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0960-0760(92)90161-B","article-title":"Characterization and coupling of angiotensin-II receptor subtypes in cultured bovine adrenal fasciculata cells","volume":"43","author":"Ouali","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/pr.112.007278_bib314","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/HJH.0b013e32834dde5f","article-title":"Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-\u03b3 activation in human monocytes","volume":"30","author":"Pang","year":"2012","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib315","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.110.067066","article-title":"Functional selectivity in adrenergic and angiotensin signaling systems","volume":"78","author":"Patel","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib316","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/00912700022009099","article-title":"The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis","volume":"40","author":"Pedro","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib317","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/ajh.2010.241","article-title":"Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats","volume":"24","author":"Pelisch","year":"2011","journal-title":"Am J Hypertens"},{"key":"10.1124\/pr.112.007278_bib318","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1210\/endo.133.4.8404609","article-title":"The type 1 angiotensin-II receptor mediates intracellular calcium mobilization in rat luteal cells","volume":"133","author":"Pepperell","year":"1993","journal-title":"Endocrinology"},{"key":"10.1124\/pr.112.007278_bib319","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3565(25)22844-0","article-title":"In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions","volume":"271","author":"Perrier","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib320","doi-asserted-by":"crossref","first-page":"C750","DOI":"10.1152\/ajpcell.1992.263.4.C750","article-title":"Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule","volume":"263","author":"Poggioli","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1124\/pr.112.007278_bib321","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0968-0896(01)00059-1","article-title":"Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of \u03c0*\u2014\u03c0* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists","volume":"9","author":"Polevaya","year":"2001","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/pr.112.007278_bib322","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0014-2999(98)00329-X","article-title":"Evaluation of the ability of irbesartan to cross the blood-brain barrier following acute intragastric treatment","volume":"352","author":"Polidori","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib323","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/j.1471-4159.1992.tb10065.x","article-title":"AT1 angiotensin receptors mobilize intracellular calcium in a subclone of NG108-15 neuroblastoma cells","volume":"58","author":"Ransom","year":"1992","journal-title":"J Neurochem"},{"key":"10.1124\/pr.112.007278_bib324","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1016086930019","article-title":"Effects of structural modifications on the intestinal permeability of angiotensin II receptor antagonists and the correlation of in vitro, in situ, and in vivo absorption","volume":"13","author":"Ribadeneira","year":"1996","journal-title":"Pharm Res"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib325","first-page":"S29","article-title":"Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexetil","volume":"11","author":"Riddell","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib326","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1021\/jm00077a007","article-title":"6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships","volume":"36","author":"Ries","year":"1993","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib327","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2174\/138161209788923859","article-title":"Are the pleiotropic effects of telmisartan clinically relevant?","volume":"15","author":"Rizos","year":"2009","journal-title":"Curr Pharm Des"},{"key":"10.1124\/pr.112.007278_bib328","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0165-6147(94)90156-2","article-title":"Agonist-antagonist interactions at angiotensin receptors: application of a two-state receptor model","volume":"15","author":"Robertson","year":"1994","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pr.112.007278_bib329","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0167-0115(94)90029-9","article-title":"Modulation of tachyphylaxis to angiotensin II in rabbit isolated aorta by the angiotensin AT1 receptor antagonist, losartan","volume":"50","author":"Robertson","year":"1994","journal-title":"Regul Pept"},{"key":"10.1124\/pr.112.007278_bib330","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1476-5381.1994.tb14036.x","article-title":"A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys","volume":"111","author":"Roccon","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib331","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1177\/0091270008317847","article-title":"Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil","volume":"48","author":"Rohatagi","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib332","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00125-010-1744-6","article-title":"Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice","volume":"53","author":"Rong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1124\/pr.112.007278_bib333","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1124\/pr.108.000612","article-title":"Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine","volume":"60","author":"Rosskopf","year":"2008","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pr.112.007278_bib334","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1177\/00912700122010645","article-title":"The pharmacokinetics of irbesartan in hypertensive children and adolescents","volume":"41","author":"Sakarcan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s002280050629","article-title":"Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19)","volume":"55","author":"Sandwall","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib336","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1476-5381.2010.00875.x","article-title":"beta-Arrestin 1 and 2 stabilize the angiotensin II type I receptor in distinct high-affinity conformations","volume":"161","author":"Sanni","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib337","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s11095-007-9401-6","article-title":"Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers","volume":"25","author":"Sato","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/pr.112.007278_bib338","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/HYPERTENSIONAHA.107.104570","article-title":"Effect of telmisartan on nitric oxide\u2014asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor \u03b3 and peroxisome proliferator activated receptor \u03b3 signaling during endothelial aging","volume":"51","author":"Scalera","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib339","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/HJH.0b013e328336b86b","article-title":"Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age","volume":"28","author":"Schaefer","year":"2010","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib340","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0026-895X(25)08561-X","article-title":"Interaction between the nonpeptide angiotensin antagonist SKF-108,566 and histidine 256 (HisVI:16) of the angiotensin type 1 receptor","volume":"47","author":"Schambye","year":"1995","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib341","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1476-5381.1994.tb16899.x","article-title":"Mutations in transmembrane segment VII of the AT1 receptor differentiate between closely related insurmountable and competitive angiotensin antagonists","volume":"113","author":"Schambye","year":"1994","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib342","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/jm0204237","article-title":"Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites","volume":"46","author":"Schmidt","year":"2003","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib343","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s002280050406","article-title":"An interaction study with cimetidine and the new angiotensin II antagonist valsartan","volume":"53","author":"Schmidt","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib344","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.2337\/diabetes.54.12.3442","article-title":"Molecular characterization of new selective peroxisome proliferator-activated receptor \u03b3 modulators with angiotensin receptor blocking activity","volume":"54","author":"Schupp","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/pr.112.007278_bib346","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-\u03b3 activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"},{"key":"10.1124\/pr.112.007278_bib347","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/00912700122010393","article-title":"Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects","volume":"41","author":"Schwocho","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib348","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2165\/00003495-200868090-00005","article-title":"Olmesartan medoxomil: a review of its use in the management of hypertension","volume":"68","author":"Scott","year":"2008","journal-title":"Drugs"},{"key":"10.1124\/pr.112.007278_bib349","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5414\/CPP40035","article-title":"Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design","volume":"40","author":"S\u00e9chaud","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib350","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00228-003-0664-5","article-title":"Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects","volume":"59","author":"Sekino","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib351","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/HJH.0b013e328165d159","article-title":"Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker","volume":"25","author":"Shao","year":"2007","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib352","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0022-3565(24)39054-8","article-title":"Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan","volume":"294","author":"Shetty","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib353","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0022-3565(25)38306-0","volume":"266","author":"Shibouta","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib354","first-page":"432","article-title":"Pharmacokinetics of 14C-telmisartan (2): plasma concentration and distribution of 14C-telmisartan after repeated oral administration to rats","volume":"14","author":"Shimasaki","year":"1999","journal-title":"Xenobio Metabol Dispos"},{"key":"10.1124\/pr.112.007278_bib355","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.nucmedbio.2012.01.008","article-title":"Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3","volume":"39","author":"Shimizu","year":"2012","journal-title":"Nucl Med Biol"},{"key":"10.1124\/pr.112.007278_bib356","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3317\/jraas.2002.046","article-title":"The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease","volume":"3","author":"Sica","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1124\/pr.112.007278_bib357","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/00003088-200038060-00005","article-title":"Pharmacokinetics and blood pressure response of losartan in end-stage renal disease","volume":"38","author":"Sica","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib358","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004872-199507001-00007","article-title":"The pharmacokinetics of losartan in renal insufficiency","volume":"13","author":"Sica","year":"1995","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/pr.112.007278_bib359","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0009-9236(97)90080-1","article-title":"The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis","volume":"62","author":"Sica","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/(SICI)1099-081X(199805)19:4<237::AID-BDD100>3.0.CO;2-7","article-title":"The effect of age on the pharmacokinetics of valsartan","volume":"19","author":"Sioufi","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.112.007278_bib361","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1124\/pr.112.007278_bib362","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/sj.bjp.0703150","article-title":"Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers","volume":"129","author":"Soldner","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib363","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1023\/A:1011902625609","article-title":"Grapefruit juice activates P-glycoprotein-mediated drug transport","volume":"16","author":"Soldner","year":"1999","journal-title":"Pharm Res"},{"key":"10.1124\/pr.112.007278_bib364","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1254\/jjp.79.131","article-title":"Inhibition of the angiotensin II Type 1 receptor by TCV-116: quantitation by in vitro autoradiography","volume":"79","author":"Song","year":"1999","journal-title":"Jpn J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib365","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1476-5381.1991.tb12503.x","article-title":"Access of peripherally administered DuP 753 to rat brain angiotensin II receptors","volume":"104","author":"Song","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib366","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/0006-291X(90)91993-3","article-title":"Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II","volume":"169","author":"Speth","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib367","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/009127000004001202","article-title":"Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib368","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/009127000004001209","article-title":"The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib369","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/009127000004001206","article-title":"Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib370","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1177\/009127000004001208","article-title":"Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib371","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1177\/009127000004001205","article-title":"Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib372","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1177\/009127000004001204","article-title":"Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib373","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/147323000002800401","article-title":"Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients","volume":"28","author":"Stangier","year":"2000","journal-title":"J Int Med Res"},{"key":"10.1124\/pr.112.007278_bib374","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1177\/009127000004001207","article-title":"Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers","volume":"40","author":"Stangier","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib375","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/00005344-200111000-00004","article-title":"Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge","volume":"38","author":"Stangier","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/pr.112.007278_bib376","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0090-9556(25)06520-1","article-title":"Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members","volume":"23","author":"Stearns","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib377","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S0090-9556(25)09049-X","article-title":"Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753","volume":"19","author":"Stearns","year":"1991","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib378","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0090-9556(25)08584-8","article-title":"The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns","year":"1992","journal-title":"Drug Metab Dispos"},{"issue":"6B","key":"10.1124\/pr.112.007278_bib379","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/j.1582-4934.2009.00829.x","article-title":"Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells","volume":"14","author":"Steinmetz","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1124\/pr.112.007278_bib380","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2362.2008.02025.x","article-title":"Angiotensin inhibition stimulates PPARgamma and the release of visfatin","volume":"38","author":"Storka","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1124\/pr.112.007278_bib381","first-page":"111","article-title":"Binding properties of telmisartan (micardis) for human angiotensin II receptors","volume":"13","author":"Sudoh","year":"2003","journal-title":"Clin Pharmacol Ther (Tokyo)"},{"key":"10.1124\/pr.112.007278_bib382","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1097\/HJH.0b013e3282f9b58a","article-title":"Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-\u03b3 dependent pathway","volume":"26","author":"Sugimoto","year":"2008","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib383","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0022-3565(25)22812-9","article-title":"Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle","volume":"271","author":"Sung","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib384","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1185\/030079906X167471","article-title":"Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects","volume":"23","author":"Sunkara","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pr.112.007278_bib385","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","article-title":"Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism","volume":"53","author":"Suwannakul","year":"2008","journal-title":"J Hum Genet"},{"key":"10.1124\/pr.112.007278_bib386","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1291\/hypres.24.65","article-title":"Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure","volume":"24","author":"Suzuki","year":"2001","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib387","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s002280050731","article-title":"In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists","volume":"56","author":"Taavitsainen","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib388","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1210\/en.2008-0502","article-title":"A selective peroxisome proliferator-activated receptor-\u03b3 modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones","volume":"150","author":"Tagami","year":"2009","journal-title":"Endocrinology"},{"key":"10.1124\/pr.112.007278_bib389","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.1998.00636.x","article-title":"Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics","volume":"45","author":"Taguchi","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib390","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/mp200160t","article-title":"The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [\u00b9\u00b9C]telmisartan","volume":"8","author":"Takashima","year":"2011","journal-title":"Mol Pharm"},{"key":"10.1124\/pr.112.007278_bib391","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005344-199711000-00011","article-title":"Pharmacologic profiles of KRH-594, a novel nonpeptide angiotensin II-receptor antagonist","volume":"30","author":"Tamura","year":"1997","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 12","key":"10.1124\/pr.112.007278_bib392","first-page":"205","article-title":"Regulation of cardiac angiotensinogen mRNA in vivo and in vitro","volume":"12","author":"Tamura","year":"1997","journal-title":"Heart Vessels"},{"key":"10.1124\/pr.112.007278_bib393","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0022-5347(17)35685-9","article-title":"Angiotensin II receptors in the rat urinary bladder smooth muscle: type 1 subtype receptors mediate contractile responses","volume":"150","author":"Tanabe","year":"1993","journal-title":"J Urol"},{"key":"10.1124\/pr.112.007278_bib394","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10157-008-0067-0","article-title":"Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics","volume":"13","author":"Tanaka","year":"2009","journal-title":"Clin Exp Nephrol"},{"key":"10.1124\/pr.112.007278_bib395","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2133\/dmpk.24.376","article-title":"Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic\/pharmacodynamic analysis","volume":"24","author":"Tanigawara","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib396","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2133\/dmpk.19.15","article-title":"Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method","volume":"19","author":"Tatami","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib397","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/j.1875-9114.1998.tb03825.x","article-title":"Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan","volume":"18","author":"Tenero","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1124\/pr.112.007278_bib398","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/(SICI)1099-081X(199809)19:6<351::AID-BDD115>3.0.CO;2-V","article-title":"Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food","volume":"19","author":"Tenero","year":"1998","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.112.007278_bib399","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2125.1998.00778.x","article-title":"Effect of age and gender on the pharmacokinetics of eprosartan","volume":"46","author":"Tenero","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib400","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1345\/aph.17188","article-title":"Effect of ranitidine on the pharmacokinetics of orally administered eprosartan, an angiotensin II antagonist, in healthy male volunteers","volume":"32","author":"Tenero","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1124\/pr.112.007278_bib401","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1161\/HYPERTENSIONAHA.108.126656","article-title":"Inhibition of tumor necrosis factor-\u03b1-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-\u03b3 with nuclear factor kappaB and CCAAT\/enhancer-binding protein-\u03b2","volume":"53","author":"Tian","year":"2009","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib402","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2012.01.026","article-title":"Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-\u03b3 in subtotal nephrectomized rat","volume":"685","author":"Toba","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib403","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.bbrc.2011.06.012","article-title":"Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-\u03b3-dependent activity","volume":"410","author":"Toyama","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib404","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1751-7176.2008.00022.x","article-title":"Efficacy, safety, and pharmacokientics of candesartan cilexetil in hypertensive children aged 5 to 17 years","volume":"10","author":"Trachtman","year":"2008","journal-title":"J Clin Hypertens (Greeenwich)"},{"key":"10.1124\/pr.112.007278_bib405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0022-3565(25)24448-2","article-title":"Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure","volume":"272","author":"Trippodo","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib406","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1172\/JCI1899","article-title":"Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes","volume":"101","author":"Tsuchida","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1124\/pr.112.007278_bib407","doi-asserted-by":"crossref","unstructured":"Tsukamoto O and Kitakaze M (2013) It is time to reconsider the cardiovascular protection afforded by RAAS blockade-overview of RAAS systems. Cardiovasc Drugs Ther DOI 10.1007\/s10557-011-6361-1.","DOI":"10.1007\/s10557-011-6361-1"},{"key":"10.1124\/pr.112.007278_bib408","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.bbrc.2011.04.142","article-title":"Irbesartan attenuates ischemic brain damage by inhibition of MCP-1\/CCR2 signaling pathway beyond AT\u2081 receptor blockade","volume":"409","author":"Tsukuda","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/pr.112.007278_bib409","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/HYPERTENSIONAHA.109.136879","article-title":"Cognitive deficit in amyloid-\u03b2-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-\u03b3 activation","volume":"54","author":"Tsukuda","year":"2009","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib410","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1745-7254.2008.00839.x","article-title":"Electropharmacological properties of telmisartan in blocking hKv1.5 and HERG potassium channels expressed on Xenopus laevis oocytes","volume":"29","author":"Tu","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/pr.112.007278_bib411","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clpt.2003.08.001","article-title":"Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91\/3 genotype","volume":"74","author":"Uchida","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib412","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/j.1552-4604.1998.tb04809.x","article-title":"Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers","volume":"38","author":"Vachharajani","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib413","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1552-4604.1998.tb04449.x","article-title":"Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers","volume":"38","author":"Vachharajani","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib414","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1365-2125.1998.00837.x","article-title":"The effects of age and gender on the pharmacokinetics of irbesartan","volume":"46","author":"Vachharajani","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib415","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mce.2008.06.006","article-title":"Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism","volume":"302","author":"Van Liefde","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"Suppl 2","key":"10.1124\/pr.112.007278_bib416","first-page":"S27","article-title":"Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers","volume":"11","author":"van Lier","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.1124\/pr.112.007278_bib417","first-page":"299","article-title":"Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters","volume":"143","author":"Van Rossum","year":"1963","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1124\/pr.112.007278_bib418","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bjp.0702398","article-title":"Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors","volume":"126","author":"Vanderheyden","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib419","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1023\/A:1007600924033","article-title":"Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors","volume":"17","author":"Vanderheyden","year":"2000","journal-title":"Pharm Res"},{"key":"10.1124\/pr.112.007278_bib420","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/bjs.1800810609","article-title":"Influence of Losartan, an angiotensin receptor antagonist, on neointimal proliferation in cultured human saphenous vein","volume":"81","author":"Varty","year":"1994","journal-title":"Br J Surg"},{"key":"10.1124\/pr.112.007278_bib421","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0006-2952(00)00546-3","article-title":"A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists","volume":"61","author":"Vauquelin","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pr.112.007278_bib422","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1472-8206.2000.tb00443.x","article-title":"Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors","volume":"14","author":"Verheijen","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib423","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib424","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/sj.bjp.0700897","article-title":"In vitro and in vivo effects of UP 269-6, a new potent orally active nonpeptide angiotensin II receptor antagonist, on vascular smooth muscle cell proliferation","volume":"120","author":"Virone-Oddos","year":"1997","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib425","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00004872-200106001-00005","article-title":"Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil","volume":"19","author":"von Bergmann","year":"2001","journal-title":"J Hypertens Suppl"},{"key":"10.1124\/pr.112.007278_bib426","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1291\/hypres.19.75","article-title":"Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats","volume":"19","author":"Wada","year":"1996","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib427","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0014-2999(94)90753-6","article-title":"Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone","volume":"253","author":"Wada","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib428","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1161\/HYPERTENSIONAHA.107.099028","article-title":"Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-\u03b3","volume":"51","author":"Walcher","year":"2008","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib429","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/004982597240767","article-title":"Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose","volume":"27","author":"Waldmeier","year":"1997","journal-title":"Xenobiotica"},{"key":"10.1124\/pr.112.007278_bib430","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-3565(25)10995-6","article-title":"Renin-angiotensin system inhibition reduces glycine-induced glomerular hyperfiltration in conscious rats","volume":"261","author":"Wang","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib431","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.2165\/00003495-200262090-00005","article-title":"Olmesartan medoxomil","volume":"62","author":"Warner","year":"2002","journal-title":"Drugs"},{"key":"10.1124\/pr.112.007278_bib432","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/STROKEAHA.110.583948","article-title":"Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-\u03b3 activation in mice with chronic cerebral hypoperfusion","volume":"41","author":"Washida","year":"2010","journal-title":"Stroke"},{"key":"10.1124\/pr.112.007278_bib433","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/dmd.110.036129","article-title":"Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments","volume":"39","author":"Watanabe","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib434","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1021\/jm00108a043","article-title":"1-(Carboxybenyl)imidazole-5-acrylic acids: potent and selective angiotensin receptor antagonists","volume":"34","author":"Weinstock","year":"1991","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib435","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/bdd.699","article-title":"Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters","volume":"31","author":"Weiss","year":"2010","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.112.007278_bib436","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-3565(25)21024-2","article-title":"Beta adrenoceptor subtype binding activity in plasma and beta blockade by propranolol and beta-1 selective bisoprolol in humans. Evaluation with Schild-plots","volume":"246","author":"Wellstein","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib437","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-006-0121-3","article-title":"Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo","volume":"62","author":"Wennerholm","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib438","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00004872-199402000-00003","article-title":"Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat","volume":"12","author":"Wienen","year":"1994","journal-title":"J Hypertens"},{"key":"10.1124\/pr.112.007278_bib439","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1527-3466.2000.tb00039.x","article-title":"A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist","volume":"18","author":"Wienen","year":"2000","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1124\/pr.112.007278_bib440","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib441","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0026-895X(25)09255-7","article-title":"Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies","volume":"41","author":"Wienen","year":"1992","journal-title":"Mol Pharmacol"},{"key":"10.1124\/pr.112.007278_bib442","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0009-9236(98)90163-1","article-title":"Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers","volume":"63","author":"Williamson","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib443","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib444","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000139357","article-title":"Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan","volume":"52","author":"Wong","year":"1996","journal-title":"Pharmacology"},{"key":"10.1124\/pr.112.007278_bib445","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0022-3565(25)19984-9","article-title":"Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent","volume":"252","author":"Wong","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib446","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/01.HYP.15.6.823","article-title":"Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753","volume":"15","author":"Wong","year":"1990","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib447","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/01.HYP.15.5.459","article-title":"Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X","volume":"15","author":"Wong","year":"1990","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib448","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(25)12755-9","article-title":"Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent","volume":"255","author":"Wong","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pr.112.007278_bib449","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1113\/jphysiol.2007.138578","article-title":"Involvement of an enterocyte renin-angiotensin system in the local control of SGLT1-dependent glucose uptake across the rat small intestinal brush border membrane","volume":"584","author":"Wong","year":"2007","journal-title":"J Physiol"},{"key":"10.1124\/pr.112.007278_bib450","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.07.001","article-title":"Brain renin-angiotensin\u2014a new look at an old system","volume":"95","author":"Wright","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1124\/pr.112.007278_bib451","first-page":"782","article-title":"Pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers of different gender","volume":"62","author":"Xu","year":"2007","journal-title":"Pharmazie"},{"key":"10.1124\/pr.112.007278_bib452","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/FPC.0b013e3283482502","article-title":"The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers","volume":"21","author":"Yamada","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/pr.112.007278_bib453","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1124\/dmd.107.017459","article-title":"Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor","volume":"35","author":"Yamada","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib454","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cvr\/cvn064","article-title":"Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization","volume":"79","author":"Yamada","year":"2008","journal-title":"Cardiovasc Res"},{"key":"10.1124\/pr.112.007278_bib455","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2174\/092986608785203746","article-title":"Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation","volume":"15","author":"Yamagishi","year":"2008","journal-title":"Protein Pept Lett"},{"key":"10.1124\/pr.112.007278_bib456","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1161\/HYPERTENSIONAHA.109.138750","article-title":"Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-\u03b3 activation","volume":"54","author":"Yamamoto","year":"2009","journal-title":"Hypertension"},{"key":"10.1124\/pr.112.007278_bib457","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1124\/dmd.105.008938","article-title":"Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans","volume":"34","author":"Yamashiro","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib458","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1211\/jpp.58.11.0011","article-title":"Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4","volume":"58","author":"Yamashita","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/pr.112.007278_bib459","doi-asserted-by":"crossref","first-page":"208","DOI":"10.18433\/J3SK5V","article-title":"Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats","volume":"15","author":"Yan","year":"2012","journal-title":"J Pharm Pharm Sci"},{"key":"10.1124\/pr.112.007278_bib460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1021\/jm950450f","article-title":"Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds","volume":"39","author":"Yanagisawa","year":"1996","journal-title":"J Med Chem"},{"key":"10.1124\/pr.112.007278_bib461","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2710.2011.01279.x","article-title":"Pharmacokinetics of losartan and its active carboxylic acid metabolite E-3174 in five ethnic populations of China","volume":"37","author":"Yang","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/pr.112.007278_bib462","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11596-008-0512-z","article-title":"Telmisartan but not valsartan inhibits TGF-\u03b2-mediated accumulation of extracellular matrix via activation of PPARgamma","volume":"28","author":"Yao","year":"2008","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1124\/pr.112.007278_bib463","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1742-7843.2008.00283.x","article-title":"Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)","volume":"103","author":"Yasar","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pr.112.007278_bib464","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.1365-2125.2002.01646.x","article-title":"Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity","volume":"54","author":"Yasar","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib465","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2002.121216","article-title":"Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype","volume":"71","author":"Yasar","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pr.112.007278_bib466","first-page":"1051","article-title":"Role of CYP2C9 polymorphism in losartan oxidation","volume":"29","author":"Yasar","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib467","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1023\/A:1011930411574","article-title":"Correlating partitioning and caco-2 cell permeability of structurally diverse small molecular weight compounds","volume":"15","author":"Yazdanian","year":"1998","journal-title":"Pharm Res"},{"key":"10.1124\/pr.112.007278_bib468","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1291\/hypres.31.1549","article-title":"Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan","volume":"31","author":"Yin","year":"2008","journal-title":"Hypertens Res"},{"key":"10.1124\/pr.112.007278_bib469","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/147323000803600204","article-title":"Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-\u03b3 activation","volume":"36","author":"Yoshida","year":"2008","journal-title":"J Int Med Res"},{"key":"10.1124\/pr.112.007278_bib470","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1007\/s00125-006-0437-7","article-title":"Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation","volume":"49","author":"Yoshida","year":"2006","journal-title":"Diabetologia"},{"key":"10.1124\/pr.112.007278_bib471","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2165\/00003088-200544120-00011","article-title":"Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients","volume":"44","author":"Yoshihara","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pr.112.007278_bib472","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/009127000004001203","article-title":"Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects","volume":"40","author":"Young","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pr.112.007278_bib473","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.metabol.2009.11.013","article-title":"Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-\u03b3 activation","volume":"59","author":"Younis","year":"2010","journal-title":"Metabolism"},{"key":"10.1124\/pr.112.007278_bib474","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0090-9556(25)06533-X","article-title":"Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174","volume":"23","author":"Yun","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pr.112.007278_bib475","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00007691-200108000-00008","article-title":"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers","volume":"23","author":"Zaidenstein","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1124\/pr.112.007278_bib476","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1152\/ajpendo.00024.2007","article-title":"Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties","volume":"293","author":"Zanchi","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/pr.112.007278_bib477","doi-asserted-by":"crossref","first-page":"PL75","DOI":"10.1016\/S0024-3205(98)00278-1","article-title":"Angiotensin II signaling activiates the NO-CGMP pathway in rat proximal tubules","volume":"63","author":"Zhang","year":"2012","journal-title":"Life Sci"},{"key":"10.1124\/pr.112.007278_bib478","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0014-2999(94)90183-X","article-title":"A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations","volume":"252","author":"Zhang","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pr.112.007278_bib479","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00169271","article-title":"Characterization of the angiotensin II-receptor subtype in the longitudinal smooth muscle of the rat portal vein","volume":"347","author":"Zhang","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/pr.112.007278_bib480","first-page":"569","article-title":"Pharmacokinetics of telmisartan in healthy Chinese subjects after oral administration of two dosage levels.","volume":"56","author":"Zhang","year":"2006","journal-title":"Arzneimittelforschung"},{"key":"10.1124\/pr.112.007278_bib481","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1463-1326.2011.01471.x","article-title":"Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats","volume":"13","author":"Zhao","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pr.112.007278_bib482","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/bdd.664","article-title":"Transport characteristics of candesartan in human intestinal Caco-2 cell line","volume":"30","author":"Zhou","year":"2009","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/pr.112.007278_bib483","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0731-7085(01)00603-3","article-title":"Structure elucidation and conformational properties of eprosartan, a non peptide angiotensin II AT1 antagonist","volume":"28","author":"Zoumpoulakis","year":"2002","journal-title":"J Pharm Biomed Anal"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724010548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pr.112.007278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T05:22:58Z","timestamp":1739856178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724010548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":482,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0031699724010548"],"URL":"https:\/\/doi.org\/10.1124\/pr.112.007278","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pr.112.007278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}